Gilead Sciences, Inc. $GILD Shares Bought by Nkcfo LLC

Nkcfo LLC lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 41.1% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 62,285 shares of the biopharmaceutical company’s stock after purchasing an additional 18,140 shares during the quarter. Gilead Sciences comprises about 2.1% of Nkcfo LLC’s holdings, making the stock its 12th biggest holding. Nkcfo LLC’s holdings in Gilead Sciences were worth $6,914,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the business. Norges Bank acquired a new stake in Gilead Sciences during the 2nd quarter worth approximately $2,150,268,000. Ameriprise Financial Inc. grew its stake in shares of Gilead Sciences by 397.6% in the second quarter. Ameriprise Financial Inc. now owns 6,748,403 shares of the biopharmaceutical company’s stock worth $748,147,000 after acquiring an additional 5,392,191 shares in the last quarter. Invesco Ltd. increased its position in shares of Gilead Sciences by 33.5% during the second quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock worth $1,499,098,000 after acquiring an additional 3,394,330 shares during the period. Assenagon Asset Management S.A. raised its stake in shares of Gilead Sciences by 164.4% in the third quarter. Assenagon Asset Management S.A. now owns 3,489,062 shares of the biopharmaceutical company’s stock valued at $387,286,000 after acquiring an additional 2,169,266 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in Gilead Sciences by 1.6% in the second quarter. Vanguard Group Inc. now owns 119,364,226 shares of the biopharmaceutical company’s stock valued at $13,233,912,000 after purchasing an additional 1,893,401 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead agreed to acquire Arcellx in a deal valued at about $7.8B (cash $115/share + $5 CVR), giving Gilead full control of Anito‑cel, a next‑generation CAR‑T for multiple myeloma that could reach regulators this year — a clear strategic boost to Gilead’s oncology franchise. Gilead Sciences to Acquire Arcellx
• Positive Sentiment: Sell‑side support: Needham reaffirmed a “buy” on GILD with a $170 price target, highlighting upside based on pipeline and M&A execution, which provides analyst backing for the medium‑term thesis. Analyst Reaffirmation (Benzinga)
• Neutral Sentiment: Gilead scheduled several investor‑conference presentations (TD Cowen, Leerink, Barclays) in early March — useful for management to frame the Arcellx rationale and provide pipeline / guidance color. Gilead to Present at Upcoming Investor Conferences
• Neutral Sentiment: Health‑care sector dynamics and a mixed broader market (including a late‑day drop in the Dow) are a moderating force — sector strength earlier in the session partly offset by broader risk‑off moves. Sector Update (Yahoo Finance)
• Negative Sentiment: A law firm (Kahn Swick & Foti) is investigating the Arcellx sale for adequacy of price and process, which raises the risk of litigation or a proxy fight that could complicate closing or create management distraction. Arcellx Investor Alert (BusinessWire)
• Negative Sentiment: Market concern about the premium and $7.8B price tag (deal cited as ~68–80% premium) is weighing on Gilead — investors are parsing near‑term cash/valuation impact, integration risk and whether the price fairly reflects risk for an outpatient oncology program. Deal Coverage (Reuters)

Insider Transactions at Gilead Sciences

In other news, Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction dated Friday, November 28th. The stock was sold at an average price of $125.08, for a total value of $625,400.00. Following the completion of the sale, the director directly owned 8,920 shares of the company’s stock, valued at approximately $1,115,713.60. The trade was a 35.92% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Daniel Patrick O’day sold 115,640 shares of the company’s stock in a transaction dated Friday, January 23rd. The shares were sold at an average price of $135.00, for a total value of $15,611,400.00. Following the completion of the sale, the chief executive officer directly owned 566,698 shares of the company’s stock, valued at approximately $76,504,230. This trade represents a 16.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 319,891 shares of company stock worth $45,091,556. 0.27% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on GILD shares. Wolfe Research upped their price target on Gilead Sciences from $155.00 to $170.00 and gave the stock an “outperform” rating in a report on Thursday, February 12th. Citigroup upped their target price on shares of Gilead Sciences from $140.00 to $156.00 and gave the stock a “buy” rating in a research note on Tuesday, January 27th. Oppenheimer raised their target price on shares of Gilead Sciences from $128.00 to $165.00 and gave the company an “outperform” rating in a report on Wednesday, February 11th. BMO Capital Markets boosted their price target on shares of Gilead Sciences from $135.00 to $150.00 and gave the stock an “outperform” rating in a report on Monday, January 26th. Finally, TD Cowen increased their price objective on shares of Gilead Sciences from $145.00 to $160.00 and gave the company a “buy” rating in a research report on Wednesday, February 11th. Twenty-three investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $155.44.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $149.83 on Tuesday. The company has a quick ratio of 1.31, a current ratio of 1.68 and a debt-to-equity ratio of 1.03. Gilead Sciences, Inc. has a 52 week low of $93.37 and a 52 week high of $157.29. The firm’s 50 day moving average is $134.07 and its two-hundred day moving average is $124.08. The firm has a market capitalization of $185.89 billion, a P/E ratio of 22.13, a P/E/G ratio of 2.01 and a beta of 0.36.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.83 by $0.03. The business had revenue of $7.93 billion during the quarter, compared to analysts’ expectations of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The company’s revenue for the quarter was up 4.7% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be issued a dividend of $0.82 per share. The ex-dividend date of this dividend is Friday, March 13th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 annualized dividend and a dividend yield of 2.2%. Gilead Sciences’s dividend payout ratio is 46.68%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.